These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32731087)

  • 21. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanil ide derivatives.
    Matsuhisa A; Tanaka A; Kikuchi K; Shimada Y; Yatsu T; Yanagisawa I
    Chem Pharm Bull (Tokyo); 1997 Nov; 45(11):1870-4. PubMed ID: 9396163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
    Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intranephron localization and regulation of the V1a vasopressin receptor during chronic metabolic acidosis and dehydration in rats.
    Tashima Y; Kohda Y; Nonoguchi H; Ikebe M; Machida K; Star RA; Tomita K
    Pflugers Arch; 2001 Aug; 442(5):652-61. PubMed ID: 11512020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular Protection and Decongestion Without Renin-Angiotensin-Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor Antagonist.
    Kolkhof P; Pook E; Pavkovic M; Kretschmer A; Buchmüller A; Tinel H; Delbeck M; Mondritzki T; Wasnaire P; Dinh W; Truebel H; Hüser J; Schmeck C
    J Cardiovasc Pharmacol; 2019 Jul; 74(1):44-52. PubMed ID: 31274842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasopressin V1a receptors mediate the hypertensive effects of [Pyr
    Griffiths PR; Lolait SJ; Harris LE; Paton JFR; O'Carroll AM
    J Physiol; 2017 Jun; 595(11):3303-3318. PubMed ID: 28255983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.
    Kondo K; Ogawa H; Yamashita H; Miyamoto H; Tanaka M; Nakaya K; Kitano K; Yamamura Y; Nakamura S; Onogawa T; Mori T; Tominaga M
    Bioorg Med Chem; 1999 Aug; 7(8):1743-54. PubMed ID: 10482466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Probing the V1a vasopressin receptor binding site with pyroglutamate-substituted linear antagonists.
    Howl J; Yarwood NJ; Stock D; Wheatley M
    Neuropeptides; 1996 Feb; 30(1):73-9. PubMed ID: 8868303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions.
    Bossmar T; Brouard R; Döberl A; Akerlund M
    Br J Obstet Gynaecol; 1997 Apr; 104(4):471-7. PubMed ID: 9141585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Binding of the non-peptide vasopressin V1a receptor antagonist SR-49059 in the rat brain: an in vitro and in vivo autoradiographic study.
    Tribollet E; Raufaste D; Maffrand J; Serradeil-Le Gal C
    Neuroendocrinology; 1999 Feb; 69(2):113-20. PubMed ID: 9986924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptors.
    Ala Y; Morin D; Mahé E; Cotte N; Mouillac B; Jard S; Barberis C; Tribollet E; Dreifuss JJ; Sawyer WH; Wo NC; Chan WY; Kolodziejczyk AS; Cheng LL; Manning M
    Eur J Pharmacol; 1997 Jul; 331(2-3):285-93. PubMed ID: 9274991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological profile of VP-343, a novel selective vasopressin V2 receptor antagonist, in rats.
    Naito A; Ohtake Y; Hasegaw H; Fukaya AY; Kurasawa T; Naito K; Matsukawa H; Oguma T; Ezure Y; Tsuriya Y; Tanaka H; Koike K; Shigenobu K
    Biol Pharm Bull; 2000 Feb; 23(2):182-9. PubMed ID: 10706381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.
    Cotte N; Balestre MN; Aumelas A; Mahé E; Phalipou S; Morin D; Hibert M; Manning M; Durroux T; Barberis C; Mouillac B
    Eur J Biochem; 2000 Jul; 267(13):4253-63. PubMed ID: 10866830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arginine-Vasopressin Receptor Blocker Conivaptan Reduces Brain Edema and Blood-Brain Barrier Disruption after Experimental Stroke in Mice.
    Zeynalov E; Jones SM; Seo JW; Snell LD; Elliott JP
    PLoS One; 2015; 10(8):e0136121. PubMed ID: 26275173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior.
    Bleickardt CJ; Mullins DE; Macsweeney CP; Werner BJ; Pond AJ; Guzzi MF; Martin FD; Varty GB; Hodgson RA
    Psychopharmacology (Berl); 2009 Mar; 202(4):711-8. PubMed ID: 18923820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of the binding sites of the SR49059 nonpeptide antagonist into the V1a vasopressin receptor using sulfydryl-reactive ligands and cysteine mutants as chemical sensors.
    Tahtaoui C; Balestre MN; Klotz P; Rognan D; Barberis C; Mouillac B; Hibert M
    J Biol Chem; 2003 Oct; 278(41):40010-9. PubMed ID: 12869559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new linear V1A vasopressin antagonist and its use in characterizing receptor/G protein interactions.
    Strakova Z; Kumar A; Watson AJ; Soloff MS
    Mol Pharmacol; 1997 Feb; 51(2):217-24. PubMed ID: 9203626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 4,10-dihydro-5H-thieno[3,2-c][1]benzazepine derivatives and 9,10-dihydro-4H-thieno[2,3-c][1]benzazepine derivatives as orally active arginine vasopressin receptor antagonists.
    Aranapakam V; Albright JD; Grosu GT; Chan PS; Coupet J; Saunders T; Ru X; Mazandarani H
    Bioorg Med Chem Lett; 1999 Jul; 9(13):1733-6. PubMed ID: 10406632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.
    Bolognani F; Del Valle Rubido M; Squassante L; Wandel C; Derks M; Murtagh L; Sevigny J; Khwaja O; Umbricht D; Fontoura P
    Sci Transl Med; 2019 May; 11(491):. PubMed ID: 31043521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spinal vasopressin alleviates formalin-induced nociception by enhancing GABAA receptor function in mice.
    Peng F; Qu ZW; Qiu CY; Liao M; Hu WP
    Neurosci Lett; 2015 Apr; 593():61-5. PubMed ID: 25782631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group.
    Shimada Y; Akane H; Taniguchi N; Matsuhisa A; Kawano N; Kikuchi K; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Tsunoda T; Tanaka A
    Chem Pharm Bull (Tokyo); 2005 Jul; 53(7):764-9. PubMed ID: 15997131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.